The global demand for the diabetes medicine Ozempic, containing semaglutide, is causing shortages in several countries due to its off-label use for weight loss. Novo Nordisk, the manufacturer, cites ongoing supply constraints. The company plans a $6 billion investment by 2029 to boost production. Britain and Belgium have restricted prescriptions for weight loss, and Germany considers banning exports due to affordability-driven demand.
